Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.
Restenosis is the major limitation of the successful therapy of percutaneous coronary intervention (PCI) for patients with coronary artery disease. The problem was appreciated in the late 1970s to early 1980s. Only in recent years, anti-restenotic therapy has achieved a breakthrough with the development of drug-eluting stents. Here, we provide an overview about pathological mechanisms of restenosis after PCI. Present therapeutic approaches to overcome restenosis and recent clinical results are revisited, and some major concerns in the post-drug-eluting stent era are discussed.
Birkenhauer
Peter
P
Institute of Pharmaceutical Sciences, ETH Hönggerberg HCI, 8093 Zürich, Switzerland.
Yang
Zhihong
Z
Gander
Bruno
B
D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease; D023903:Coronary Restenosis / Q000503:physiopathology* / Q000517:prevention & control*; D016503:Drug Delivery Systems; D006801:Humans; D015607:Stents